期刊文献+

洛沙坦对高血压大鼠血管平滑肌细胞凋亡及凋亡基因Bax和Bcl-2的影响(英文) 被引量:2

Effects of Antihypertensive Therapy with Losartan on VSMC Apoptosis in Spontaneously Hypertensive rats
暂未订购
导出
摘要 目的研究血管紧张素Ⅱ ATI-R阻滞剂洛沙坦对自发性高血压大鼠(SHR)血管平滑肌细胞(VSMC)凋亡及凋亡基因Bax、Bcl-2的影响。方法末端标记法(TUNEL)检测细胞凋亡及RT—PCR、免疫组化方法分别检测Bax、Bcl-2基因及其蛋白的表达。结果从(12~24)周龄,SHR VSMC凋亡逐渐减低,24周龄时,凋亡指数(APOI)低于同周龄正常血压大鼠(WKY)(P〈0.05);洛沙坦应用8周和12周。使APOI增加71%、35%(P〈0.05)。随大鼠周龄增加,SHR胸主动脉Bax基因表达逐渐下调。与APOI变化趋势一致。洛沙坦降压治疗可使SHR胸主动脉Bax蛋白表达上调。Bcl-2蛋白下调。结论洛沙坦长期降压治疗促进Bax蛋白表达和/或抑制Bcl-2蛋白表达,其机制可促进VSMC凋亡。 Objective To explore the effects of the antihypertensive therapy with Losartan on vascular smooth muscle cell (VSMC) apoptosis and apoptotic gene Bax, Bcl-2 in spontaneously hypertensive rats (SHRs). Methods Apoptosis was identified by in situ TDT- mediated dUTP nick end labeling (TUNEL). The expression of Bax and Bcl - 2 gene was detected by RT - PCR, and their protein expression was assessed by immunohistochemistry. Results The results showed that the APOI of VSMC apoptosis in SHR - C decreased gradually with their aging from 12 weeks old to 24 weeks old; and was lower than that of age - matched WKY at the age of 24 weeks (P 〈 0, 05 ). Losartan increased APOI by 71%, 35 % after oral use for 8 weeks and 12 weeks (P 〈 0.05 ). Expression of proapoptotic gene Bax in thoracic aorta tissue of SHR - C decreased gradually from 12 weeks to 24 weeks with the same trend as that of APOI. The antihypertensive therapy by losartan might make the upregulation of the expression of Bax protein in thoracic aorta and the downregulation of Bcl - 2 protein. Conclusion The long - term antihypertensive therapy with Losartan stimulated the expression of Bax protein and/or inhibits the expression of Bcl - 2 pro- tein, Its mechanism might be to promote the vascular smooth muscle cell apoptosis.
出处 《中西医结合心脑血管病杂志》 2006年第1期46-50,共5页 Chinese Journal of Integrative Medicine on Cardio-Cerebrovascular Disease
关键词 细胞凋亡 高血压病 洛沙坦 大鼠 apoptosis hypertension Losartan
  • 相关文献

参考文献22

  • 1Heagerty AM,Aalkjaer C,Bund SJ,et al.Small artery structure in hypertension:Dual processes of remodeling and growth[J].Hypertension,1993,21:391-397.
  • 2Folkow B.Physiological aspects of primary hypertension[J].Physiol Rev,1982,62:347-504.
  • 3Mulvany MJ.Are vascular abnormalities a primary cause or secondary consequence of hypertension[J].Hypertension,1991,18(suppl I):52-57.
  • 4CLee RMKW,Smeda JS.Primary versus secondary structural changes of the blood vessels in hypertension[J].Can J Physiol Pharmacol,1985,63:392-401.
  • 5Schiffrin EL.Reactivity of small blood vessels in hypertension:Relation with structure changes[J].Hypertension,1992,19(suppl II):1-9.
  • 6Lee RM,Owens GK,Scott-Burden T,et al.Pathophysiology of smooth muscle in hypertension[J].Can J Physiol Pharmacol,1995,73:574-584.
  • 7CFolkow B.Structure factor in primary and secondary hypertension[J].Hypertension,1990,16:89-101.
  • 8Safar ME,Laurent S.Behaviour of conduit arteries in hypertension [J].Clin Exp Hypertens,1993,15:1033-1045.
  • 9CWalter SV,Hamet P.Enhanced DNA synthesis in heart and kidney of newborn spontaneously hypertensive rats[J].Hypertension,1986,8:520-525.
  • 10Owens GK.Control of hypertrophic versus hyperplastic growth of vascular smooth muscle cells[J].Am J Physiol,1989,257(6 pt2):755-765.

同被引文献28

引证文献2

二级引证文献14

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部